Concordia International Corp (TSE:CXR) (NASDAQ:CXRX) Director John Beighton sold 34,000 shares of Concordia International stock in a transaction on Monday, March 19th. The stock was sold at an average price of C$0.75, for a total value of C$25,500.00.

Concordia International Corp (TSE CXR) traded down C$0.05 during midday trading on Tuesday, hitting C$0.70. The stock had a trading volume of 120,894 shares, compared to its average volume of 130,743. The company has a market cap of $38.43, a PE ratio of -0.02 and a beta of -1.38. Concordia International Corp has a 12 month low of C$0.58 and a 12 month high of C$2.88.

COPYRIGHT VIOLATION WARNING: “John Beighton Sells 34,000 Shares of Concordia International Corp (CXR) Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at

About Concordia International

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with's FREE daily email newsletter.